Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

RDN-929

Other · developed by Alkermes

Phase 1 Most advanced trial (none active)

ALKS Developer

2 Registered trials

What is RDN-929?

RDN-929 is an investigational drug studied in Healthy.

At a glance

Drug type: Other
Developer: Alkermes, Inc. (ALKS)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03963973	Phase 1	Healthy	Terminated	ALKS
NCT03668314	Phase 1	Healthy	Completed	ALKS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy

More from Alkermes

Aripiprazole Lauroxil FDA approved Samidorphan FDA approved Alixorexton Phase 3 ALKS 1140 Phase 1 ALKS 2680 Phase 2/3 ALKS 3831 Phase 3 ALKS 5461 Phase 3 ALKS 7290 Phase 2

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the ALKS page.

Follow ALKS, the company behind RDN-929

See ALKS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ALKS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z